The financials
AbCellera Biologics Inc. by the numbers
AbCellera Biologics Inc. (ABCL) reported revenue of $8.3M in Q1 2026 (quarter ended March 31, 2026), up 96% from the same quarter a year earlier. That came with net loss of $43M. For the full year FY2025, revenue was $75M (+161% year on year) and net income −$146M. Its largest product in 2026-Q1 was Research Fees at $8.1M, 98% of the disclosed total, just ahead of Licensing And Royalty at 2.3%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $8.3M | $4.2M | +96% |
| Operating income | −$58M | −$63M | n/a |
| Net income | −$43M | −$46M | n/a |
| Diluted EPS | −$0.14 | −$0.15 | n/a |
| Product | Revenue | Share |
|---|---|---|
| Research Fees | $8.1M | 98% |
| Licensing And Royalty | $191K | 2.3% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $8.3M (-7.1%)
Research Fees grew +100% year on yearLicensing And Royalty +14% year on year
Segment Latestquarter on quarteryear on year
- Research Fees$8.1M$8.1MQoQ -7.9%year on year +100%-7.9%+100%
- Licensing And Royalty$191.0K$191.0KQoQ -year on year +14%-+14%
- License--QoQ -year on year ---
- Milestone Payments--QoQ -year on year ---